



Moderna's PharmD Fellowship Program

Table of contents

- 3 Company background
- 4 Moderna's pipeline
- 5 Moderna's values
- 5 Moderna's mindsets
- 6 Fellowship offerings
- 8 Clinical Operations
- 10 Clinical Safety and Pharmacovigilance
- 12 Global Regulatory Science
- 14 Massachusetts College of Pharmacy and Health Sciences
- 15 Application and recruitment process



Moderna, in collaboration with MCPHS, is pleased to offer this unique postdoctoral fellowship program to expose qualified Doctor of Pharmacy graduates to the biopharmaceutical industry, and to enhance the role of pharmacists within this field. The fellowship is two years in duration and will be based out of Moderna's headquarters in Cambridge, Massachusetts.

Stéphane Bancel

Chief Executive Officer of Moderna



Company background



Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.

Our mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, we strive to deliver the greatest possible impact to people through mRNA medicines.

Our first commercial product, Spikevax (our COVID-19 vaccine), has helped hundreds of millions of people worldwide combat COVID-19. Our second commercial product, mRESVIA, an RSV vaccine, was approved by the FDA in May 2024. mNEXSPIKE, our third commercial product, was approved in 2025.

Having demonstrated clinical benefit in multiple infectious disease areas and skin cancer, as well as potential clinical benefit for several rare genetic diseases, we continue to advance a broad and diverse pipeline and are focused on execution to deliver for patients. Our pipeline includes 47 therapeutic and vaccine programs, nine of which are in late-stage development.

To learn more, visit [modernatx.com](https://www.modernatx.com).



Moderna's mission is to **deliver** the greatest possible **impact** to people through mRNA **medicines**.

Moderna's pipeline

Infectious disease vaccines			Ph 1	Ph 2	Ph 3	Commercial
Respiratory viruses	COVID-19 vaccine	Spikevax®				
	COVID-19 vaccine	mNEXSPIKE®				
	RSV vaccine	mRESVIA®				
	Flu + COVID vaccine	mCOMBRIAX®				
	Flu vaccine	mFLUSIVA®				
	Pandemic Flu vaccine (in collaboration with CEPI*)	mRNA-1018				
	RSV + hMPV vaccine	mRNA-1365				
	RSV vaccine for adolescents + pediatrics	mRNA-1345				
Enteric viruses	Norovirus vaccines	mRNA-1403				
		mRNA-1405				
Latent viruses	CMV vaccine for transplant recipients	mRNA-1647				
	EBV vaccine to prevent infectious mononucleosis	mRNA-1189				
	EBV vaccine to address long term EBV sequelae	mRNA-1195				
	HIV vaccine (in collaboration with IAVI)	mRNA-1645				
Bacterial	Lyme disease vaccines	mRNA-1975				
		mRNA-1982				
Public health	Nipah vaccine	mRNA-1215				
	Mpox vaccine	mRNA-1769				
Oncology therapeutics			Ph 1	Ph 2	Ph 3	Commercial
Intismeran autogene (partnered with Merck)	Adjuvant melanoma	mRNA-4157				
	Adjuvant NSCLC	mRNA-4157				
	Adjuvant NSCLC non-pCR post neoadjuvant	mRNA-4157				
	Adjuvant Stage 1 NSCLC	mRNA-4157				
	Adjuvant renal cell carcinoma (RCC)	mRNA-4157				
	Adjuvant bladder cancer (MIBC)	mRNA-4157				
	Bladder cancer (NMIBC)	mRNA-4157				
	Metastatic melanoma	mRNA-4157				
	First-line metastatic squamous NSCLC	mRNA-4157				
	Early and advanced solid tumors	mRNA-4157				
Cancer antigen therapies	Advanced solid tumors	mRNA-4359				
	Solid tumors	mRNA-4106				
	Solid tumors	mRNA-4200				
	Lynch Syndrome	mRNA-4194				
T-cell engagers	Multiple myeloma	mRNA-2808				
Cell therapy enhancers	Solid tumors (in collaboration with Immatics)	mRNA-4203 + anzu-cel (IMA203)				
Rare disease therapeutics			Ph 1	Ph 2	Ph 3	Commercial
Rare diseases	Propionic acidemia	mRNA-3927				
	Methylmalonic acidemia	mRNA-3705				

Moderna's values

Our values are built on a foundation of quality, integrity, and respect.



Bold

Deliver on the promise of mRNA technology to transform the lives of patients. Be a visionary.



Collaborative

Accomplish goals by working together and respecting others' viewpoints. Be a part of one team.



Curious

Seek to challenge and improve upon the status quo. Be innovative.



Relentless

Stay undaunted by challenges and build quickly on successes. Be tenacious in pursuit of our mission for patients.

Moderna's mindsets



We act with urgency

Action today compounds the lives saved tomorrow.



We pursue options in parallel

to make the best choice later.



We accept risk

as the only path to impact.



We obsess over learning

We don't have to be the smartest—we have to learn the fastest.



We pivot fearlessly

in the face of new data.



We question convention

because proven models don't always fuel the future.



We push past possible

because greatness lives outside of comfort zones.



We behave like owners

The solutions we're building go beyond any job description.



We act with dynamic range

driving strategy and execution at the same time and at every step.



We remove viscosity

to encourage collective action.



We prioritize the platform

over any single product.



We digitize everywhere possible

using the power of digital information to maximize our impact on patients.



Fellowship offerings

Clinical Operations

1 Position

Clinical Safety and Pharmacovigilance

1 Position

Global Regulatory Science

Not recruiting for 2027

Clinical Operations

1 position



Renamed in loving memory of its co-founder, the **Dr. Runa Mithani PharmD Fellowship in Clinical Operations** honors Runa's legacy. A Purdue PharmD graduate ('07), she spent more than a decade in clinical operations—first as GSK's Local Delivery Lead for vaccine studies across Africa, the Middle East, and Eastern Europe, then in the U.S. as Senior Clinical Project Manager. She later directed clinical operations at Moderna, guiding the launch of mRESVIA, the first mRNA RSV vaccine.

Runa's devotion to patients and to mentoring fellows shaped the program from its first year, when she served as clinical operations preceptor. Colleagues remember her as an "all-rounder" whose energy, laughter, and generosity united teams and friends alike. **Runa was a beloved member of the Moderna family and the team is honored to continue this program as part of her lasting legacy.**

The Clinical Operations & Program Management PharmD Fellowship at Moderna offers a unique opportunity to experience the full continuum of drug and vaccine development from research through clinical development, regulatory approval, commercialization, and lifecycle management. Fellows gain broad exposure to the cross-functional teams that bring innovative mRNA medicines and vaccines from scientific discovery to patients around the world. Our portfolio covers a wide variety of products in Oncology, Infectious Disease, Rare Disease, and more.

What sets this fellowship apart is its integrated two-year structure. During the first year, fellows work within Clinical Operations, gaining hands-on experience in the planning, execution, and oversight of clinical studies while protecting participant safety and data reliability. In the second year, fellows transition to Program Management, where they contribute to the strategic leadership of cross-functional development programs, gaining insight into end-to-end program oversight, decision-making, and portfolio execution.

Projects are assigned to each fellow based on Moderna's development goals and business needs while also including each fellow's interests, providing opportunities to build both operational expertise and strategic leadership skills. This combination of study-level and program-level experience prepares fellows for diverse career paths across the biopharmaceutical industry.

CO CURRENT FELLOWS



Alyssa Ghiles, PharmD, MPH

Second-Year Fellow
University of North Carolina at Chapel Hill



Joshua Airgood, PharmD

First-Year Fellow
University of North Carolina at Chapel Hill

CO FELLOWSHIP CORE TEAM



Andrea Feller, PhD, MHS

Senior Director, Program Management
CO PharmD Fellowship Program Lead



Sinead Rudden, PhD

Director, Clinical Operations
CO PharmD Fellowship Preceptor



Allison Lin, PharmD, RPh

Senior Manager, Program Management
CO PharmD Fellowship Preceptor



Conor Knightly, MPH

Senior Vice President, Head of Global
Development Operations – Development



Christy Shaw, PhD

Head, Program Development

Clinical Safety and Pharmacovigilance

1 position



Moderna Clinical Safety and Pharmacovigilance (CSPV) is committed to advancing patient safety with next generation mRNA science. The fellow will engage in diverse projects from a benefit-risk analysis perspective, contributing to the product portfolio, including individual case assessments, safety monitoring, medical review, and responding to health authority requests. They will gain an in-depth understanding of various safety functions, with exposure to safety governance, data analytics, and both routine and post-marketing surveillance. Additionally, the fellow will support the development of aggregate reports and gain a comprehensive understanding of product submission activities.

The two-year CSPV Fellowship will provide PharmD graduates with a fast-paced environment and introduction to the pharmaceutical industry across a diverse pipeline. As integral members of the Moderna team, fellows will acquire practical experience through direct engagement with subject matter experts, participate in cross-functional team collaborations, and benefit from valuable networking and mentorship opportunities.

The fellow will have exposure to the following functional areas throughout their fellowship:

- Signal Management
- Clinical Trials/Post-Marketing
- Aggregate Reports
- Risk Management
- Optional elective

Projects will be assigned based on the fellow's areas of interest and available opportunities to build the fellow's competencies as a pharmacovigilance professional.

CSPV CURRENT FELLOWS



Jennifer Lee, PharmD, RPh

Second-Year Fellow
MCPHS University



Abigail Bakus, PharmD

First-Year Fellow
University of Pittsburgh

CSPV FELLOWSHIP CORE TEAM



Rebecca Lackey, PharmD

Director, Clinical Safety Program Lead
CSPV PharmD Fellowship Program Lead



Kinjal Kashyap, PharmD, RPh

Director, Risk Management



Tony Rizk, PharmD, MBA

Senior Manager, Clinical Safety Scientist
CSPV PharmD Fellowship Preceptor



Melissa Rossi, MPH

Executive Director, Head of Clinical
Safety Sciences



José M. Vega, MD

Senior Vice President, Chief Safety Officer

Global Regulatory Science

Not recruiting for 2027



The Global Regulatory Science (GRS) department drives rapid and efficient development of molecules and medicinal products derived from an mRNA platform. We hope to ensure patient access to transformative therapies, while building a sustainable and resilient function within Moderna. The fellow will join the Global Regulatory Science team in Cambridge, Massachusetts.

The 2-year Global Regulatory Science Program will provide PharmD graduates the opportunity to gain rapid experience in the pharmaceutical industry within Regulatory Science while working on diverse projects to deepen their understanding of product development.

The fellow will focus on Regulatory Strategy and may take part in projects covering 2-3 regulatory specialties, including:

- Regulatory Labeling
- Regulatory Policy
- Regulatory Operations
- Regulatory CMC
- International Regulatory Affairs

Projects will be assigned based on the fellow's areas of interest and available opportunities to build the fellow's competencies as a regulatory professional. Additionally, the fellow may have the option to take part in a 1-3 month rotation in another department outside of Global Regulatory Science at Moderna.

GRS CURRENT FELLOW



Kishan Patel, PharmD

Second-Year Fellow
MCPHS University-Worcester

GRS FELLOWSHIP CORE TEAM



Anna Prisco, PharmD, RPh

Senior Manager, Global Regulatory Strategy
GRS PharmD Fellowship Program Lead and Preceptor



Antonella Lozito, PharmD

Vice President, Global Regulatory Strategy



Julie Romanelli, MS, MPH

Director, Global Regulatory Advertising
and Promotion



Lori Sorial, PharmD

Associate Director, Global Regulatory
Strategy



**Charbel Haber, MPH,
PhD, MBA**

Senior Vice President, Head of Global
Regulatory Science

MCPHS Biopharmaceutical Industry Fellowship Program

MCPHS

MCPHS provides an academic environment to guide and support fellows toward a successful career in the biopharmaceutical industry. As a private institution with a history of specializing in health sciences, MCPHS offers programs that embody scholarship, professional service, and community outreach.

Through MCPHS, fellows will have the opportunity to gain teaching and scholarship experience. Throughout the program, MCPHS faculty will be paired with fellows to mentor them and help them achieve their teaching and scholarly goals.

As a postdoctoral fellow at MCPHS, each fellow may have the opportunity to

- Develop, coordinate, and teach pharmacy courses
- Co-precept students on advanced experiential rotations
- Assist in the publication of scholarly research and review articles
- Present data at scientific and clinical meetings
- Participate in professional development seminars

MCPHS PHARMD FELLOWSHIP PROGRAM TEAM

Amee Mistry, PharmD, RPh
Director of the Postdoctoral
Biopharmaceutical Industry Fellowship Program

Dr. Amee Mistry is Professor of Pharmacy Practice and has been with MCPHS since 2006. Dr. Mistry earned her PharmD at the Albany College of Pharmacy and completed a PGY1 Community Practice Residency with Walgreens and MCPHS. In 2015, Dr. Mistry took over as Director of the MCPHS Biopharmaceutical Industry Fellowship program. She works directly with leaders in the area to continue to foster growth and development of the post-graduate program, and to assist the fellows in attaining positions within the pharmaceutical industry. In addition, she is advisor for the student IPhO chapter at MCPHS, co-advisor for APhA-ASP, a national trainer for the APhA Pharmacy-Based Immunization training program, and is actively involved with the Massachusetts Pharmacists Association.

Samantha Nganju, MBA
Fellowship Program Manager
MCPHS

Alaina Buldini
Program Coordinator
MCPHS

Application & recruitment process

Application Requirements

ELIGIBILITY

The MCPHS Biopharmaceutical Industry fellows will be selected on a nationally competitive basis.

- Applicants must have a Doctor of Pharmacy degree from an ACPE accredited college of pharmacy at the commencement of the program.
- Candidates must have strong written and verbal communication skills and a strong interest in pursuing a career within the biopharmaceutical industry.
- All candidates must have authorization to work in the United States throughout the duration of the one or two year fellowship. No visa sponsorship will be provided (i.e., TN, H-1B, STEM OPT, etc.).

APPLICATION PROCEDURE

The MCPHS application portal (SMAApply) will open on **Monday, October 5, 2026**. Applicants must upload the following application materials to the **online portal** (<https://mcphs.smapply.io>) no later than **Monday, November 2, 2026**:

- Letter of intent (addressed to the company specific program director/lead; found in each company brochure)
- Curriculum vitae
- Unofficial college transcript
- Contact information for three references. References will receive an electronic recommendation form to complete separately.

Three recommendation evaluation forms must be submitted no later than **Friday, November 20, 2026** via the online portal. This is NOT a letter of recommendation but an online form that the recommender will receive for completion from SMAApply.

APPLICATION REVIEW AND INTERVIEW TIMELINE

Following a review of submitted applications, pre-screens and preliminary interviews will begin in October. Additional interviews, including final rounds will take place in December during ASHP. Candidates will be notified if selected for an interview. The process is rigorous and competitive; therefore, candidates should submit their applications well in advance of posted deadlines as priority will be given to those who apply early.

ASHP MIDYEAR & ONSITE INTERVIEWS

The fellowship program will be conducting **in-person interviews** at the ASHP Midyear Clinical Meeting in Orlando, FL. Attendance is strongly encouraged, but not required. Please refer to the ASHP & PPS website for registration details.

Top candidates may be invited for interviews at the sponsoring company's location.

AIFA FIRST OFFER DATE

The choice of a Post-Doctoral Fellowship is an important decision. MCPHS, in conjunction with the Alliance of Industry Fellowship Associates (AIFA), has aligned to extend offers for Fellowships no earlier than **Friday, December 11, 2026**. We believe this is a positive reflection of the cultures our Programs offer, and that culture is a critical consideration in choice of Fellowship.

We hope that other academic and non-academic Fellowship Programs will NOT pressure candidates to accept offers prior to this aligned offer date.

ONBOARDING

Final candidates will be required to go through additional screening/onboarding as required by MCPHS.

Please visit the MCPHS biopharmaceutical industry fellowship website for more information:

<https://www.mcphs.edu/faculty-and-research/fellowships-and-residencies/biopharmaceutical-fellowships>



moderna®

 **MCPHS**
BIOPHARMACEUTICAL INDUSTRY
FELLOWSHIP PROGRAM